Phosplatin Therapeutics

Phosplatin Therapeutics is a private clinical-stage drug development company focused on oncology treatment, having conducted multiple clinical trials in the United States and Europe. The company's lead candidate, PT-112, has a pleiotropic mechanism of action that functions as a monotherapy and in combination with checkpoint inhibition to induce immunogenic cell death (ICD). Phosplatin Therapeutics holds the exclusive global license for a novel family of compounds, including its lead compound PT-112. Currently in Phase II drug development, the company is conducting three ongoing trials targeting solid tumors and hematological oncology, treating numerous patients to date. Notably, Phosplatin Therapeutics has received orphan drug designation for thymoma and multiple myeloma and is designing a Phase III clinical trial for a cancer indication with high unmet medical need.